Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EP Vantage Pharma Half-Year Review 2013
In this latest report from EP Vantage, based on EvaluatePharma market intelligence, the editorial team have analysed some of the key trends that have defined the industry in the first six months of the year and look to what might happen during the remainder of 2013.
The report reveals that despite a positive start to the year, characterised by healthy IPO activity and free-flowing venture capital, licensing deals, the life blood of the industry, have stalled. Although caution abounds, the industry is still on track to meet 2013 market expectations.
Key findings of the report include:
- IPO activity continues to increase as 20 companies floated in the first half of the year raising $1.28bn between them. Only 16 companies completed IPO’s during the whole of 2012.
- $2 billion in venture finance raised in first half with two thirds of total coming in the second quarter.
- A total of 416 licensing deals were closed, with $1.59 million changing hands in the first half of 2013. Given these weak numbers, the industry may struggle to match the total of 2012, which was the slowest in at least five years.
- The pharma industry saw $29 billion worth of M&A transactions in the first six months, putting 2013 on track to be the best year since 2010 (excluding mega-mergers).
- US product approvals have nearly matched the encouraging pace of 2012, with 17 approved by June 30. Should the 29 small-molecule therapies and nine biological agents make it to the market this year, projected five-year US sales will reach $16.3 billion, above the $15.9 billion projected from 2012.
Read Press Release